Mycophenolic Acid (MPA) and Metabolite
Use
The test is used to monitor therapeutic levels and evaluate toxicity of mycophenolic acid (MPA), the active metabolite of the prodrug mycophenolate mofetil (MMF). MPA acts by blocking inosine 5′-monophosphate dehydrogenase (IMPDH) in lymphocytes, thus depleting guanosine triphosphate (GTP) pools and inhibiting T lymphocyte activation. This mechanism also makes MPA an adjuvant with highly active antiretroviral therapy (HAART) for limiting availability of target cells for HIV.
Special Instructions
MPA and its glucuronide metabolite have high protein binding at clinical concentrations. The test may show varied results if used in combination with calcineurin inhibitors such as cyclosporine or tacrolimus.
Limitations
The test has been developed by LabCorp with its performance characteristics determined by them, but it has not been cleared or approved by the FDA. Potential interactions may occur between MPA and calcineurin inhibitors like cyclosporine, impacting serum concentrations of both MPA and its glucuronide.
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 87432-1
- 23905-3
- 23906-1
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
1.2 mL
Minimum Volume
0.3 mL
Container
Red-top tube or lavender-top (EDTA) tube
Collection Instructions
Transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Room temperature
Causes for Rejection
Gel-barrier tube
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |